General | ||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||
Comparison | ||||||||||||||||||||||||||||
|
Date | For | Estimate | Reported | Surprise | surprise % |
---|---|---|---|---|---|
2024-08-08 | 2024-06 | -0.34 | N/A | N/A | N/A |
2024-05-09 | 2024-03 | -0.21 | -0.31 | -0.1 | -47.62% |
2024-03-14 | 2023-12 | 0 | -0.5 | N/A | N/A |
2024-03-14 | 2023-12 | 0 | N/A | N/A | N/A |
2023-11-09 | 2023-09 | -0.29 | -0.2 | 0.09 | 31.03% |
2023-11-09 | 2023-09 | -0.29 | N/A | N/A | N/A |
Date | Firm | Action | From | To |
---|---|---|---|---|
2023-08-13 | HC Wainwright & Co. | Upgrade | Neutral | Neutral |
2023-05-14 | HC Wainwright & Co. | Upgrade | Neutral | Neutral |
2023-03-19 | HC Wainwright & Co. | Downgrade | Buy | Neutral |
2023-02-22 | HC Wainwright & Co. | Upgrade | Buy | |
2022-11-13 | HC Wainwright & Co. | Upgrade | Buy | |
2022-08-14 | HC Wainwright & Co. | Upgrade | Buy |
Date | Name | Relation | Quantity | Description |
---|---|---|---|---|
2021-05-23 | BENSON REED L | General Counsel | 3.17K | Conversion of Exercise of derivative security |
2024-05-22 | BROWN BRIAN LEE | Chief Financial Officer | 290.69K | Stock Award(Grant) |
2024-05-22 | DURENARD EUGENE A | Director | 115.00K | Stock Award(Grant) |
2024-05-22 | EGAN DWIGHT H | Chief Executive Officer | 367.21K | Stock Award(Grant) |
2024-05-22 | MURPHY TED | Director | 127.50K | Stock Award(Grant) |
2024-05-22 | NELSON JAMES B | Director | 115.00K | Stock Award(Grant) |
Report Date | Organization | Position | Value | Percentage |
---|---|---|---|---|
2023-06-29 | Vanguard Group Inc | 1.78M | 1.98M | 5.79% |
2023-06-29 | Renaissance Technologies, LLC | 653.70K | 725.61K | 2.12% |
2023-06-29 | Blackrock Inc. | 506.51K | 562.22K | 1.65% |
2023-06-29 | Geode Capital Management, LLC | 302.16K | 335.39K | 0.98% |
2023-06-29 | Bridgeway Capital Management, Inc. | 272.90K | 302.92K | 0.89% |
2023-06-29 | Bank Of New York Mellon Corporation | 145.62K | 161.64K | 0.47% |
Report Date | Organization | Position | Value | Percentage |
---|---|---|---|---|
2023-06-29 | Vanguard Total Stock Market Index Fund | 1.28M | 1.42M | 4.15% |
2023-06-29 | Vanguard Extended Market Index Fund | 444.78K | 493.70K | 1.44% |
2023-06-29 | Bridgeway Funds Inc-Ultra Small Company Fund | 272.90K | 302.92K | 0.89% |
2023-05-30 | Fidelity Extended Market Index Fund | 165.22K | 180.09K | 0.54% |
2023-08-30 | iShares Micro Cap ETF | 69.84K | 86.60K | 0.23% |
2023-05-30 | Fidelity Total Market Index Fund | 53.59K | 58.41K | 0.17% |
Plot a 50 day exponential moving average. This stock will turn up on a weekly close above it. Otherwise, no interest. In a market which has zero interest in fundamentals, technicals rule. In a blind world, the one-eyed man rules all.
$CODX if you made a bad entry price STFU, do your DD, and buy now that it’s lower. Spike incoming IMO. Stop condemning the company. They’re making huge strides. It’s called consolidation in a major bull move.
$CODX makes total sense why this is flagging in 10s
$CODX seems to be a potentially huge upside catalyst for next quarter in new PCR based lab testing
$CODX there was obviously some consternation re August HHS and FDA testing policy. Timing of the August swoon IE, but the Nov reversion in HHS policy re FDA should have reversed sentiment you’d think.
How do y’all interpret this revised HHS instructions to FDA? I’m thinking bullish https://www.modernhealthcare.com/supply-chain/fda-told-resume-expedited-review-lab-developed-covid-tests
Got tested yesterday, unfortunately it was an Abbot test.
$CODX There’s always more than meets the eye, especially with a hard to borrow rate of 35%, coinciding with a rehashing of old news from a Massachusetts based news source. The Chairman of the Board is the former Chairman of CRMC, the investment manager of the American Funds Group 🧐
Well hello there little flag formation. Been waiting for you to show up. Nice to see you here again.
Thank you for the share Mr. Michaels
History $IBIO was built for pandemic purposes in 2010 by DARPA. In 2011 the influenza disease outbreak happened and IBIO hit their peak as a company. Then the disease died out and so did their stock price. In 2014, the outbreak of Ebola happened and so they hit another peak. Now look where we’re at now.Covid is destroying the world in many ways and people are seeing how big this has effected the world so far. IBIO was built for this exact reason. In my opinion, influenza became less dangerous as scientists have developed vaccines and the spread of Ebola died out. COVID will not die for months/years to come. $IBIO shares price in past pandemics 15$-55$, $IBIO is known for FastPharming has applications far beyond producing a COVID-19 vaccine. An example of this potential was a deal signed in October with Safi Biosolutions. The agreement will see iBio’s FastPharming system used in the bioprocessing of Safi’s blood cell therapy products. FastPharming has the potential to be part of many such deals in the future. $IBIO conference is Today (there are speculation of possible contract or partnership)
$MEDS News! Float 3m, Earnings report - Beats revenue double! Recently partnered with SingleCare, prescription saving services that provide prescription COVID drug discount, one of recently IPO, GoodRx s competitors, shares +24.68%, closed at 7.71 $WWR $ISIG $JMIA $LLIT $GRIL $SPY $GNUS $MARK $CIT $SPY $BAC $SPAQ $CODX